Gulshan Polyols FY26 net profit rises 332% to ₹107 crore
Gulshan Polyols reported a net profit of ₹107 crore for FY26, a 332% increase from ₹25 crore in FY25. Revenue rose 14% to ₹2,314 crore. The Board recommended a 150% dividend.

*this image is generated using AI for illustrative purposes only.
Gulshan Polyols has reported its audited financial results for the quarter and year ended March 31, 2026. The company recorded a total income of ₹2,314 crore for the full financial year, an increase of 14% from ₹2,025 crore in the previous year. Net profit for the year stood at ₹107 crore, compared to ₹25 crore in FY25, marking a significant improvement in annual profitability. The Board has recommended a dividend of 150%, or ₹1.50 per share, subject to shareholder approval.
Q4 Performance
For the quarter ended March 31, 2026, revenue from operations rose to ₹551 crore from ₹515 crore in the corresponding period of the previous year. Net profit for the quarter increased to ₹38 crore from ₹7 crore in Q4 FY25. EBITDA for the quarter stood at ₹65 crore, with margins expanding to 11.9% from 5.8% in the same quarter last year.
Financial Highlights
The following table summarises the key financial figures for the quarter and full year:
| Metric | Q4 FY26 | Q4 FY25 | FY26 | FY25 |
|---|---|---|---|---|
| Revenue (₹ in crores) | ₹551 | ₹515 | ₹2,312 | ₹2,020 |
| Net Profit (₹ in crores) | ₹38 | ₹7 | ₹107 | ₹25 |
Strategic Outlook
The company stated that it is targeting utilization levels of 80-90% across key divisions, which should support revenue growth towards the range of ₹2,600 to ₹2,800 crores. Management indicated that from FY28 onwards, the focus will shift towards specialty and import-substitute chemicals to move further up the value chain.
Historical Stock Returns for Gulshan Polyols
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.47% | -2.55% | +1.07% | +36.17% | -4.04% | +32.09% |
What specific factors contributed to the significant expansion in EBITDA margins during Q4 FY26?
How will the company fund the transition towards specialty and import-substitute chemicals starting FY28?
What are the expected capital expenditure requirements to achieve the targeted 80-90% utilization levels?


































